trending Market Intelligence /marketintelligence/en/news-insights/trending/6xejsl29b0o3zbaq25uupa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Mast Therapeutics lays off staff

Streaming Media Devices Feel The Squeeze In Q3'19

AT&T To Use Wireless Subs To Create Buzz For HBO

Municipal CUSIP Requests On Pace For Record Year, Thanks To October Issuance Surge

Creating an Efficient Enterprise Wide Credit Risk Management System for a Leading Energy Company


Mast Therapeutics lays off staff

Mast Therapeutics Inc. laid off some of its employees as part of a cost-cutting measure.

The restructuring is meant to return focus to AIR001, a clinical-stage investigational drug for treating patients with heart failure as a result of preserved ejection fraction.

Mast Therapeutics is exploring opportunities to monetize its Vepoloxamer programs so it could advance AIR001 instead. Vepoloxamer itself is meant to be used in the sickle cell disease and heart failure.